10-K: Novavax Swings to Profit in 2025 Amid Strategic Shifts

Sentiment:

Annual Report 26 February 2026 7:33 AM

Novavax reported a significant financial turnaround in 2025, achieving net income of $440.3 million, driven by strategic partnership milestones and cost reductions, while securing new collaborations for its Matrix-M adjuvant.

Delay expectedThe company withdrew its application for the COVID-19 Vaccine in Australia based on recommendations from the TGA, leading to ongoing discussions and potential termination of the APA if regulatory approval for a variant vaccine is not obtained or doses are not supplied per schedule.The CIC and stand-alone influenza vaccine candidates will not pursue an accelerated approval pathway, and the company is actively seeking a partner to advance these programs, indicating a potential delay in their commercialization timeline.

Capital raiseIssued $225.0 million aggregate principal amount of 4.625% Convertible Senior Notes due 2031 in August 2025.Entered into a Credit, Security, and Guaranty Agreement in February 2026 for a senior secured term loan facility of up to $330 million, with $50 million funded at closing.Approximately $51 million remains available under the August 2023 At Market Issuance Sales Agreement for potential future equity offerings.The company explicitly states it expects to require additional funds and plans to finance cash needs through a combination of milestone payments, royalties, product sales, additional public or private equity or debt financings, collaborations, strategic alliances, and asset sales.

Better than expectedReported a net income of $440.3 million in 2025, a significant improvement from a net loss of $187.5 million in 2024.Total revenue increased by $441.3 million to $1.123 billion in 2025, primarily driven by product sales.Product sales increased by $471.8 million, largely due to the recognition of deferred revenue from the termination of APAs with Canada and New Zealand.Successful execution of the Sanofi partnership resulted in $225 million in milestone payments in 2025.Secured a new strategic partnership with Pfizer for Matrix-M adjuvant, including a $30 million upfront payment.Cost of sales and selling, general, and administrative expenses decreased significantly in 2025 due to cost containment measures and restructuring.

Summary

Novavax reported a net income of $440.3 million in 2025, a substantial improvement from a net loss of $187.5 million in 2024 and $545.1 million in 2023.
Total revenue increased to $1.123 billion in 2025 from $682.2 million in 2024, primarily due to higher product sales.
Product sales surged to $685.0 million in 2025, up from $213.2 million in 2024, largely driven by the termination of Advance Purchase Agreements (APAs) with Canada ($575.7 million) and New Zealand ($27.3 million).
Licensing, royalties, and other revenue decreased to $438.4 million in 2025 from $469.0 million in 2024, mainly due to a decrease from the Sanofi Collaboration and License Agreement (CLA), partially offset by increased revenue from Takeda.
The company earned $225 million in milestone payments from Sanofi in 2025, including $175 million for U.S. FDA approval of Nuvaxovid BLA and $50 million for marketing authorization transfers.
A new License and Option Agreement was signed with Pfizer in January 2026 for the use of Novavax's Matrix-M adjuvant in up to two infectious disease areas, including a $30 million upfront payment and potential for up to $500 million in development and sales milestones.
Research and development expenses decreased to $342.3 million in 2025 from $391.2 million in 2024, reflecting cost containment measures and reduced development activities for certain vaccine candidates.
Selling, general, and administrative expenses decreased significantly to $157.5 million in 2025 from $337.2 million in 2024, due to cost containment and a reduction in global commercial footprint.
An impairment loss of $97.8 million was recognized in 2025 for assets held for sale, specifically the former corporate headquarters facility at 700 Quince Orchard Road.
Net cash used in operating activities increased to $244.6 million in 2025 from $87.3 million in 2024, primarily due to a reduction in cash received from APA receivables and the Sanofi CLA.
As of December 31, 2025, cash and cash equivalents, restricted cash, and marketable securities totaled $750.5 million, down from $938.2 million at the end of 2024.
The R21/Matrix-M adjuvant malaria vaccine, developed by a partner (Jenner Institute, University of Oxford) and manufactured by Serum Institute of India (SII), sold 30 million doses since its mid-2024 launch, achieving over 80% market share.
Takeda achieved a 12% market share with Nuvaxovid in Japan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, highlighting a significant financial turnaround to profitability and successful strategic partnerships, despite ongoing operational challenges and the need for future funding.

Positives

Achieved a significant financial turnaround, reporting a net income of $440.3 million in 2025, compared to substantial losses in prior years.
Product sales increased by $471.8 million in 2025, largely due to the recognition of deferred revenue from the termination of APAs with Canada and New Zealand.
Successfully executed the Sanofi partnership, receiving $225 million in milestone payments in 2025, including $175 million for U.S. FDA BLA approval of Nuvaxovid.
Secured a new strategic License and Option Agreement with Pfizer in January 2026 for its Matrix-M adjuvant, including a $30 million upfront payment and potential for up to $500 million in future milestones and tiered royalties.
Sanofi reported positive Phase 1/2 data for their influenza-COVID-19 combination vaccine candidates, indicating progress in a key partnered program.
The R21/Matrix-M adjuvant malaria vaccine, a partner-led product, achieved a successful launch with 30 million doses sold since mid-2024 and over 80% market share.
Takeda's commercialization of Nuvaxovid in Japan achieved a 12% market share, demonstrating regional success for the COVID-19 vaccine.
Ongoing preclinical research in high-value areas such as C. Diff, shingles, RSV combinations, and oncology, leveraging the Matrix-M technology.
Remediation of a material weakness in internal control over financial reporting identified in 2024, enhancing financial reporting reliability.
Secured a new senior secured term loan facility of up to $330 million in February 2026, with an initial $50 million funded, providing additional liquidity.

Negatives

Licensing, royalties, and other revenue decreased by $30.5 million in 2025 compared to 2024, primarily due to a decrease in revenue under the Sanofi CLA.
Withdrew the COVID-19 Vaccine application in Australia based on TGA recommendations, leading to ongoing discussions and potential refund obligations of up to $92.5 million in deferred revenue.
Net cash used in operating activities significantly increased to $244.6 million in 2025 from $87.3 million in 2024.
Incurred a $97.8 million impairment loss on assets held for sale, related to the former corporate headquarters facility.
The company has a history of losses and its future profitability remains uncertain, requiring significant ongoing funding.
The CIC and stand-alone influenza vaccine candidates will not pursue an accelerated approval pathway, and the company is seeking a partner to advance these programs, indicating potential delays in commercialization.
The company remains dependent on a single source supplier for quillaja extract, a key component of its Matrix-M adjuvant, posing supply chain risk.
The Credit Agreement entered in February 2026 contains restrictive covenants and requires significant cash for debt servicing.

Risks

History of losses and uncertain future profitability.
Requires significant funding for operations and vaccine candidates.
Existing collaboration, funding, and supply agreements do not assure success or full funding; failure to satisfy obligations may result in loss of milestone payments, termination, reduced purchase commitments, or refunds.
Limitations on the use of net operating losses and other tax attributes.
Vaccine product development and commercialization depend on new, rapidly evolving technologies with uncertain success.
Clinical and preclinical development is lengthy, expensive, and has uncertain outcomes; prior results are not necessarily predictive.
Difficulties or delays in clinical trials could increase costs, delay revenue, or adversely affect commercial prospects.
Difficulty enrolling subjects in clinical trials.
Adverse side effects or safety risks could delay/preclude approval, suspend trials, abandon candidates, limit commercial profile, or result in negative consequences.
Significant risks in developing, manufacturing, and commercializing products and vaccine candidates.
Limited marketing capabilities; dependence on marketing partners.
Regional relationships may hinder larger transactions.
Must identify vaccines for development and establish successful third-party relationships.
Reliance on third parties to conduct preclinical studies and clinical trials.
Reliance on third parties for manufacturing vaccine candidates.
Many competitors have significantly greater resources and experience.
Regulatory approval processes are lengthy, time-consuming, and unpredictable.
Business may be adversely affected by failure to execute business development initiatives.
Servicing 2031 and 2027 Notes requires significant cash flow.
Credit Agreement contains restrictions.
Stock price is highly volatile.
Litigation or regulatory investigations could have a material adverse impact.
Adversely affected by natural or man-made disasters or public health emergencies.
Inability to secure sufficient supplies of quillaja extract (key adjuvant component).
Vaccine candidates are sensitive to shipping and storage conditions.
Fast Track Designation does not assure faster development or approval.
Uncertainty with respect to pricing, third-party reimbursement, and healthcare reform.
Vaccine candidates may never achieve market acceptance.
Emergence of SARS-CoV-2 variants may affect market acceptance or sales.
Product liability exposure.
Inadequate funding for FDA, SEC, and other regulatory authorities.
Subject to environmental, health, and safety laws.
Subject to anti-bribery and anti-corruption laws and trade laws.
Inability to protect intellectual property and proprietary rights.
Former employees/consultants may wrongfully disclose trade secrets.
Inability to protect intellectual property throughout the world.
Third parties may claim infringement of intellectual property rights.
Scope, validity, and ownership of patent claims may be challenged.
Scope, validity, and ownership of trademark rights may be challenged.
Need to license intellectual property from third parties.
Changes in patent laws or interpretation may allow competitors to use discoveries.
Intellectual property rights do not necessarily provide protection against all competitive harm.
Global restructuring and cost reduction plans may disrupt business.
Security breaches and other disruptions to IT systems.
Non-compliance with global privacy and data security requirements.
Collaborations and contracts with international partners expose to additional risks.
Inability to attract or retain key management or other personnel.
Target for public scrutiny and unfavorable publicity.
Increasing use of social media platforms presents new risks.

Future Outlook

Novavax expects to fund its future operations primarily through product sales, milestone payments, royalties, and reimbursements from strategic partners, along with existing cash and marketable securities. The company anticipates requiring additional capital, potentially through equity or debt financings, collaborations, strategic alliances, and asset sales. It plans to continue its global restructuring and cost reduction measures and aims to advance at least one early-stage program into clinical trials as early as 2027, while exploring new opportunities for its Matrix-M technology beyond infectious diseases.

Management Comments

Our corporate growth strategy focuses on maximizing the impact of our cutting-edge technology by forging partnerships for our Matrix-M adjuvant and research and development (R&D) assets while maintaining a lean and focused operating model.
Our technology platform, combined with our deep vaccine expertise, is the fuel for innovation and partnerships, and we believe it has the potential to create significant value.

Industry Context

StockSavvy.ai notes that Novavax operates in a highly competitive global vaccine market, contending with major pharmaceutical companies such as Pfizer, Moderna, Sanofi, GSK, and Seqirus. The company's proprietary Matrix-M adjuvant and recombinant protein-based nanoparticle technology offer a differentiated platform, enabling dose-sparing effects and refrigerator temperature storage, which are valuable attributes in vaccine development and distribution. The new partnership with Pfizer for Matrix-M adjuvant and the strong market penetration of the R21/Matrix-M malaria vaccine underscore the commercial viability and industry recognition of Novavax's core technology. However, the evolving regulatory landscape, particularly changes in U.S. presidential administration policies and Advisory Committee on Immunization Practices (ACIP) recommendations regarding vaccines, introduces significant market and reimbursement uncertainties that could impact demand for Novavax's products and the broader vaccine industry.

Comparison to Industry Standards

Nuvaxovid is one of three COVID-19 vaccines approved by the U.S. FDA for the 2025-2026 vaccination season, positioning Novavax as a key player alongside Pfizer and Moderna.
The R21/Matrix-M adjuvant malaria vaccine, a partner-led product, achieved over 80% market share since its mid-2024 launch, demonstrating strong competitive performance in its therapeutic area.
Takeda's commercialization of Nuvaxovid in Japan secured a 12% market share, indicating successful regional market penetration against competitors.
Novavax's stand-alone influenza vaccine candidate aims to be at least as efficacious as current products or those in development by competitors, highlighting the company's focus on differentiation in a crowded seasonal influenza market dominated by major pharmaceutical companies like Sanofi, GSK, and Seqirus.
Sanofi's combination vaccine candidates (COVID-19 and influenza), utilizing Novavax's COVID-19 Vaccine, reported positive Phase 1/2 results, aiming for non-inferiority against co-administered vaccines, directly competing with similar efforts from companies like Moderna.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Consultant	NA	John Trizzino	December 18, 2025	Consulting Agreement extended through March 31, 2026. Unvested non-statutory stock options granted on March 7, 2023, immediately vested as of December 31, 2025.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	The Board of Directors is divided into three classes (Class I, Class II, Class III), with members serving staggered three-year terms. Directors are elected by a plurality of votes.	Ongoing	This classified board structure may make it more difficult for a third party to acquire control of the company or discourage takeover attempts.
Charter Amendments	Amendments to the charter relating to the number, classes, election, term, removal, vacancies, and related provisions with respect to the Board require the affirmative vote of holders of at least 75% of the shares of capital stock issued and outstanding and entitled to vote.	Ongoing	This high threshold for amendments further entrenches the current board structure and may deter hostile takeovers.
Authorized Capital Shares	The Certificate of Incorporation authorizes 600,000,000 shares of common stock and 2,000,000 shares of preferred stock, of which 438,885 shares have been designated as Series A Convertible Preferred Stock. As of December 31, 2025, no shares of Preferred Stock are outstanding.	Ongoing	Authorized but unissued shares, particularly preferred stock, can be used by the Board to impede takeover efforts without stockholder approval, depending on the terms of issuance.
Stockholder Proposals and Director Nominations	By-Laws require stockholders to provide timely advance notice (not less than 60 days nor more than 90 days prior to the anniversary date of the prior year's annual meeting) for bringing business or nominating directors.	Ongoing	These requirements can make it more challenging for dissident stockholders to influence corporate decisions or board composition.
Stockholder Action by Written Consent	The Certificate of Incorporation prohibits stockholders from acting by written consent. Special meetings of stockholders can only be called by the Board, CEO, or President.	Ongoing	This limits the ability of stockholders to take rapid action outside of scheduled meetings and can lengthen the time required for stockholder-proposed actions.
Delaware General Corporation Law Section 203	The company is subject to Section 203 of the Delaware General Corporation Law, which prohibits business combinations with an interested stockholder (15% or more ownership) for three years unless certain conditions are met.	Ongoing	This anti-takeover provision can deter unsolicited acquisition attempts not approved by the Board.
Cybersecurity Oversight	The Board considers cybersecurity risk as part of its risk oversight function and has delegated oversight of cybersecurity risks to the Audit Committee. The CIO reports periodically to the Audit Committee and Board.	Ongoing	Formalized oversight structure aims to enhance the company's ability to manage and mitigate cybersecurity threats, which is critical for protecting sensitive data and operations.

Legal Proceedings

Currently, there are no material pending legal proceedings.

Related Party Transactions

Intercompany accounts payable arising from Transfer Pricing Agreements (including intercompany Matrix-M Adjuvant sales), Terminated Transfer Pricing Agreements, or the Intercompany Matrix-M Adjuvant License Agreement are considered Permitted Debt in the Ordinary Course of Business.
Transactions with Affiliates are permitted if they are in the Ordinary Course of Business, on fair and reasonable terms, and not materially less favorable than those obtainable from a third party, or if they are among Credit Parties and not otherwise prohibited by the agreement.

Stakeholder Impact

Shareholders: Potential for increased value due to improved financial performance and strategic partnerships, but also face risks of dilution from future capital raises and stock price volatility. The impairment charge and ongoing operational losses could negatively impact investor confidence.
Employees: Affected by global restructuring and workforce reductions (25% in May 2023, additional 12% in January 2024), leading to job insecurity for some, but the company aims to attract and retain talent with competitive compensation and benefits.
Customers: Continued supply of COVID-19 Vaccine through partners like Sanofi, and potential for new vaccine products incorporating Matrix-M adjuvant, offering new treatment options. However, withdrawal of the Australian application could impact customer relationships in that region.
Partners (Sanofi, Pfizer, Takeda, SII): Strengthened collaborations and new licensing agreements (e.g., Pfizer) validate Novavax's technology and create mutual growth opportunities. Successful market penetration of partnered products (e.g., malaria vaccine) benefits all parties.
Creditors: The issuance of new convertible notes and a secured term loan facility provides capital but also increases debt obligations, requiring careful management of cash flow for repayment.
Regulatory Authorities: Ongoing engagement for product approvals and post-marketing commitments, with potential for scrutiny and impact from policy changes (e.g., ACIP recommendations affecting vaccine demand).

Next Steps

Negotiate further amendments to the Australian APA to resolve outstanding issues and obligations.
Sanofi will engage with regulatory authorities on next steps for their influenza-COVID-19 combination vaccine candidates following positive Phase 1/2 results.
Novavax intends to enter the clinic with at least one early-stage program as early as 2027.
Continue exploration of adjuvant technology to expand its utility both within infectious disease and potentially beyond, such as oncology.
Negotiate and enter into a Clinical Supply Agreement and later a Commercial Supply Agreement with Pfizer for the supply of Matrix-M adjuvant.
Continue conducting the Phase 4 post-marketing commitment trial for Nuvaxovid on behalf of Sanofi.
Continue to supply existing APA customers and strategic partners, including Takeda and SII, with COVID-19 Vaccine.
Upon completion of existing APAs, Novavax and Sanofi will jointly agree on commercialization activities in each jurisdiction.
Continue to implement global restructuring and cost reduction measures.
Evaluate business needs and opportunities to balance in-house expertise with external capacity.

Key Dates

Date	Description
March 2020	Entered into an agreement with SII for a non-exclusive license to use Matrix-M adjuvant for R21/Matrix-M malaria vaccine.
July 1, 2021	Amended and Restated Supply and License Agreement with Serum Institute of India Private Limited.
August 2022	Entered into an influenza license agreement with SII.
December 2022	Issued $175.3 million aggregate principal amount of 5.00% Convertible Senior Notes due 2027.
January 2023	Established the 2023 Inducement Plan.
May 2023	Announced a global restructuring and cost reduction plan, including an approximately 25% reduction in global workforce.
August 8, 2023	Settlement Agreement and General Release with SK bioscience Co., Ltd.
August 2023	Entered into an At Market Issuance Sales Agreement for up to $500 million in common stock, terminating the June 2021 agreement.
December 2023	WHO prequalified the R21/Matrix-M adjuvant malaria vaccine.
February 2024	Entered into a Termination and Settlement Agreement with Gavi Alliance.
January 2024	Announced an additional 12% reduction of global workforce.
May 2024	Entered into the Sanofi Collaboration and License Agreement (CLA) and a supply agreement with Serum Life Sciences Limited (SLS). Sold 6.9 million shares of common stock to Sanofi in a private placement.
July 2024	First commercial doses of R21/Matrix-M adjuvant malaria vaccine administered in Cote d'Ivoire and South Sudan.
December 2024	Entered into an amendment to the Australia APA. Initiated a Phase 3 immunogenicity and safety trial for CIC and stand-alone influenza vaccine candidates. Sanofi's combination vaccine candidates granted Fast Track designation by U.S. FDA. Sold 12.2 million shares of common stock under August 2023 Sales Agreement.
November 1, 2024	Termination and Settlement Agreement with the UK Health Security Agency.
December 11, 2024	HHS Secretary issued 12th amendment to PREP Act declaration, extending coverage to December 31, 2029.
March 2025	Received communication terminating the Canada APA. Executed a Deed of Settlement and Release with Pharmac (New Zealand Settlement Agreement).
April 29, 2025	Entered into the Amended Takeda CLA and a release agreement with Takeda.
May 2025	U.S. FDA approved the BLA for Nuvaxovid, triggering a $175 million milestone payment under the Sanofi CLA.
June 2025	Reported data from the initial cohort of Phase 3 immunogenicity and safety trial for CIC and stand-alone influenza vaccine candidates.
August 2025	U.S. FDA approved the JN.1 COVID-19 Vaccine. Issued $225.0 million aggregate principal amount of 4.625% Convertible Senior Notes due 2031.
September 2025	Amended the Sanofi CLA to expand Sanofi's license to include use of Matrix-M adjuvant in Sanofi's pandemic influenza vaccine candidate program.
October 2025	Sanofi reported positive Phase 1/2 results with their combination vaccine candidates. Initiated an additional Phase 4 post-marketing commitment study for Nuvaxovid. Entered into a definitive agreement to sell the 700 Quince Orchard Road facility.
November 2025	Completed the transfer of the Nuvaxovid BLA to Sanofi. Received initial net payment of $19.7 million related to the land sale of the 700QO facility.
December 18, 2025	Amendment to Consulting Agreement with John Trizzino, extending through March 31, 2026.
December 31, 2025	Fiscal year ended. Unvested non-statutory stock options granted to John Trizzino on March 7, 2023, immediately vested.
January 14, 2026	Entered into a License and Option Agreement with Pfizer Inc. for use of Matrix-M adjuvant.
January 2026	Received $30 million upfront payment from Pfizer. Completed the assignment of the leasehold interest in 700QO and received the remaining $39.8 million payment.
February 2026	Entered into a Credit, Security, and Guaranty Agreement with MidCap Financial Trust, funding $50 million at closing. R21/Matrix-M adjuvant malaria vaccine available in 24 countries. Expanded an existing MTA with a major global pharmaceutical company. Signed a new MTA with an oncology company.
March 1, 2031	Maturity date for the senior secured term loan facility.

Recommendation

hold

Novavax's significant shift to profitability in 2025, driven by strategic APA terminations and successful milestone achievements from the Sanofi partnership, is a strong positive. The new licensing agreement with Pfizer for the Matrix-M adjuvant further validates Novavax's core technology and opens new revenue streams. However, the company still faces considerable challenges, including a history of operational losses, the need for substantial future funding, intense competition in the vaccine market, and regulatory uncertainties such as the withdrawal of its COVID-19 vaccine application in Australia. The increased net cash used in operating activities and the restrictive covenants of the new debt facility also warrant caution. While the recent positive developments are encouraging, the long-term sustainability of profitability and the successful navigation of its pipeline and market challenges are not yet fully assured. A 'Hold' recommendation reflects the balance between these positive catalysts and the persistent risks.

Keywords

Novavax, NVAX, Vaccine, Matrix-M, COVID-19 Vaccine, Influenza Vaccine, Malaria Vaccine, Biotechnology, Pharmaceutical, SEC Filing, 10-K, Financial Results, Partnerships, Sanofi, Pfizer, Takeda, Serum Institute of India, R&D, Regulatory Approval, Debt Financing, Capital Raise, Corporate Governance, Risk Management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.